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OBJECTIVE — To assess the effects of exenatide on body weight and glucose tolerance in
nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG).
RESEARCH DESIGN AND METHODS — Obese subjects (n  152; age 46  12 years,
female82%,weight108.623.0kg,BMI39.67.0kg/m
2,IGTorIFG25%)wererandomized
toreceiveexenatide(n73)orplacebo(n79),alongwithlifestyleintervention,for24weeks.
RESULTS — Exenatide-treated subjects lost 5.1  0.5 kg from baseline versus 1.6  0.5 kg
withplacebo(exenatideplacebo,P0.001).Placebo-subtracteddifferenceinpercentweight
reduction was 3.3  0.5% (P  0.001). Both groups reduced their daily calorie intake
(exenatide,449cal;placebo,387cal).IGTorIFGnormalizedatendpointin77and56%of
exenatide and placebo subjects, respectively.
CONCLUSIONS — Exenatide plus lifestyle modiﬁcation decreased caloric intake and re-
sultedinweightlossinnondiabeticobesitywithimprovedglucosetoleranceinsubjectswithIGT
and IFG.
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S
everal well-designed trials have
demonstrated that weight reduction
can reduce diabetes risk (1–4).
However, with only lifestyle modiﬁca-
tion, even modest weight loss is difﬁcult
to achieve over time (5,6); therefore, op-
timal pharmacologic strategies for treat-
ing obesity are being developed. This
study explored exenatide in combina-
tion with lifestyle modiﬁcation as treat-
ment for weight loss in nondiabetic
obese subjects with normal glucose tol-
erance (NGT), impaired glucose toler-
ance (IGT), or impaired fasting glucose
(IFG).
RESEARCH DESIGN AND
METHODS— Obese adult subjects
with a BMI 30 kg/m
2 were included.
Subjects with type 2 diabetes, previous
use of glucose-lowering medications for
3 months, or unstable body weight be-
fore screening were excluded. At screen-
ing, subjects received an oral glucose
tolerance test to stratify into subgroups:
NGT, IGT (fasting glucose 7 mmol/l
and 2-h postprandial glucose 7.8 and
11.1 mmol/l), or IFG (fasting glucose
6.1–6.9 mmol/l and 2-h postprandial
glucose 7.8 mmol/l). Subjects then par-
ticipatedina1-weeksingle-blindplacebo
lead-in period before randomization to
exenatide (10 g with a 4-week 5-g
dose-initiation period) or placebo admin-
istered before morning and evening
meals. A structured program of diet and
physical activity was implemented
through week 24. Subjects fasted over-
night, and study drug was withheld before
oral glucose tolerance test assessments. A
follow-upvisitwasconducted4weeksafter
study completion.
The primary end point was the effect
of exenatide on body weight. Secondary
endpointsincludedassessmentofchange
in glucose and lipid concentrations, A1C,
blood pressure, physical activity, and
food intake. Primary analyses were based
on the intent-to-treat sample and a
mixed-model repeated-measures AN-
COVA. Least squares means were pro-
duced to estimate the magnitudes of
treatment effects.
RESULTS— Of 322 participants
screened, 163 were randomized, 152 re-
ceived at least one dose of study drug (in-
tent-to-treat sample), 102 completed
treatmentthrough24weeks,and96com-
pleted a follow-up visit after being off the
study drug for 4 weeks. Average BMI
was 39.6  7.0 kg/m
2, and 38 subjects
had IGT or IFG at baseline. The with-
drawal rate was 34% for exenatide and
32% for placebo; baseline characteristics
were comparable to completers. Adverse
events accounted for nine withdrawals
(ﬁve related to nausea) with exenatide
and three with placebo.
Mean baseline body weight was
109.5  2.7 and 107.6  2.6 kg with
exenatide and placebo, respectively. Ex-
enatide-treated subjects lost 5.1  0.5 kg
from baseline versus 1.6  0.5 kg with
placebo (Figure 1: exenatide  placebo,
P  0.001). A placebo-subtracted differ-
ence in percentage weight reduction was
ﬁrst observed at week 4 (0.9  0.4%,
P  0.03) and remained at week 24
(3.3  0.5%, P  0.001). Subjects who
returned after being off the study drug for
4 weeks sustained weight loss with in-
creases of only 0.5 kg in both groups. A
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subjects experienced 5% body weight
reductionat24weekscomparedwithpla-
cebo (32 vs. 17%, respectively; P 
0.039). Exenatide-treated subjects who
did (n  18) or did not (n  55) experi-
ence nausea had mean body weight re-
ductionsat24weeks(nausea:3.81.2
kg; no nausea: 4.1  0.8 kg).
Most subjects with IGT or IFG nor-
malized glucose tolerance at end point
(exenatide 77%, placebo 56%). Five par-
ticipants (three exenatide, two placebo)
developed type 2 diabetes during the
study, three of which (two exenatide, one
placebo) had IGT or IFG at baseline. Both
groups signiﬁcantly (P  0.05) reduced
their daily calorie intake (exenatide
449  64 calories; placebo 387  63
calories). Signiﬁcant baseline–to–end
pointchangeswerenotobservedforA1C,
fasting glucose, oral glucose tolerance
test,andphysicalactivity.Similarchanges
in lipid concentrations and blood pres-
sure were observed in both treatment
groups.
No deaths, serious adverse events, or
hypoglycemia were observed during the
study.Nauseawasexperiencedby25and
4% and diarrhea by 14 and 3% of ex-
enatide- and placebo-treated subjects, re-
spectively. The majority of adverse events
were mild or moderate in severity.
CONCLUSIONS — GLP-1 receptor
agonists are among the few treatments for
type 2 diabetes in which signiﬁcant
weight loss was recognized as an added
value. This study of exenatide, combined
with a pragmatic lifestyle intervention,
was designed to evaluate the potential for
weight loss in obese (mean baseline BMI
39.6 kg/m
2) nondiabetic subjects in clear
need of therapeutic intervention, as rec-
ommended by current guidelines (7,8).
Exenatide treatment plus lifestyle modiﬁ-
cation was associated with signiﬁcantly
greater mean percent reduction in body
weight (treatment difference, 3.3%)
than lifestyle modiﬁcation alone. The pla-
cebo-subtracted change in weight (3.5
kg) was similar to the change observed
with liraglutide at the 2.4-mg dose (9). It
is unknown if higher doses of exenatide
might achieve greater weight reductions
than those observed in the present study.
Although we did not evaluate possi-
blemechanismstoexplainthesubstantial
weight loss observed, GLP-1 receptor
agonism may activate central pathways
mediating satiety- and nausea-regulating
mechanisms (10,11). The ﬁnding that
weight loss in exenatide-treated sub-
jects with type 2 diabetes is sustained in
the absence of continued nausea (12)
supports a satiety-related mechanism
(10,13).
Normalization of glucose tolerance
and reduction of caloric intake favored
subjects treated with exenatide. The cur-
rent ﬁndings warrant further studies to
explore the potential role of GLP-1 recep-
tor agonists for the treatment of obese
subjects with IGT or IFG. Exenatide, in
addition to lifestyle modiﬁcation, has po-
tential as a treatment for obesity in sub-
jects at high risk for developing type 2
diabetes. Because of the high recidivism
observed with weight loss interventions,
sustained weight loss demonstrated in
long-term studies is a key issue for future
anti-obesity research.
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